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ABSTRACT 
 
 
 
 Prostate cancer (PC) that results from metastasis of the tumor primarily to the 
skeleton is among the leading causes of death for men. Involvement of the bone related 
transcription factor, Runx2, has been implicated in the progression of PC, however the 
levels of Runx2 and its targets have not been analyzed in PC.  In this project, two 
transgenic mouse models for PC, the LADY and the TRAMP, were used to analyze 
Runx2 expression. Cell lines derived from both mice models showed increased 
expression of Runx2 from sexual maturity to the advancement stages, but an absence in 
normal prostate. Tumors were isolated from the mouse prostate at different time points 
(6wk, 12wk, 16wk, and 21wk). The tissues were analyzed for protein and gene 
expression and by histology for cellular properties. In both models, we found Runx2 in 
stromal and epithelial cells of the early PIN (prostatic intraepithelial neoplasia) lesion and 
activation of Runx target genes known to promote bone metastasis in the prostate by 
week 16. These results suggest that Runx2 may be a significant protein for consideration 
as a potential new therapy for prostate cancer. 
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BACKGROUND 
 
 
 
Prostate Cancer 
Prostate cancer (PC) is among the leading causes of death for men, especially 
over the age of 75 (NIH.gov, 2010). The prostate is one of the organs of the male 
reproductive system. It is wrapped around the urethra, which explains the manifestation 
of symptoms of prostate cancer, which include trouble urinating, blood in the urine, and 
pain in the lower back or pelvic bones once the cancer has spread. There are two 
diagnostic tests for prostate cancer, a prostate biopsy, and screening for prostate prostate-
specific antigen (PSA) (NIH.gov, 2010).  PSA is a protein that dissolves the coagulation 
of seminal fluid, keeping seminal fluid liquid. Although PSA is used as a diagnostic test 
for prostate cancer, it is more accurately a marker of an enlarged prostate (Kim, 2011).   
The current treatments for prostate cancer include surgery, radiation therapy, 
and/or hormone therapy (NIH.gov, 2010).  In hormone replacement therapy, also termed 
androgen ablation therapy, testosterone levels are lowered using medications like Lupron 
or Zoladex to inhibit the production of testosterone in the testes (KnowCancer.com, 
2009).  Lowering testosterone levels usually slows tumor growth because initially the 
tumor growth is dependent on the presence of testosterone.  However, after an initial 
response to this treatment, many cancers become androgen-independent, meaning the 
tumor continues to grow in the absence of testosterone (Sartor, 2005). Because androgen 
ablation therapy is not 100% successful, there is a need for new therapies to treat prostate 
cancer.  Over the past decade, antibodies or drugs have been designed that inhibit 
proteins involved in PC growth and/or cell survival, but these drugs have shown limited 
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success.  Once PC tumors become aggressive, there is a very high frequency of 
metastasis to the lung, and especially to bone. 
 
Prostate Cancer Mouse Models 
Two mouse models have been used to study prostate cancer. The first is known as 
the LADY mouse. This model uses the probasin (epithelial) promoter to drive the 
expression of the late T antigen, which has a mutation that removes the expression of the 
small T antigen, which encodes tumor suppressor proteins. Thus, in this model, the late T 
antigen is expressed in epithelial cells, causing tumor formation of the prostate.  
However, metastasis is not common in this model (Gipp et al., 2007).  
The TRAMP mouse uses the probasin promoter to drive expression of the SV40 T 
antigen to cause orthotropic prostate tumors (Greenberg et al., 1995; Gingrich et al., 
1996). Many stages of prostate cancer have been observed in the TRAMP model. This 
model is reliable, and adenocarcinomas (AC) were found in 100% of TRAMP mice 
between 10 and 20 weeks of age (Sharma, and Schreiber-Agus, 1999).  Adenocarcinomas 
are advanced lesions occurring after the first stage PIN (prostatic intraepithelial 
neoplasia) lesion (Figure-1). AC lesions are found in human PC’s, and therefore the 
TRAMP mouse is a relevant model for human PC.  
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Figure-1: Advanced Stages of Mouse Prostate Cancer.  
(Adapted from: Abate-Shen et al, Genes & Dev, 2000) 
 
Prostate Cancer Progression and Runx2 
The Runx proteins are transcription factors involved in hematopoiesis (Runx1), 
osteogenesis (Runx2), and tumor suppression (Runx3). Mutations in the Runx proteins 
are also involved in cancer development.   
Runx2 is a transcription factor with a well characterized function in bone 
morphogenesis (Akech et al., 2010). However, Runx2 is also expressed in a variety of 
tissues other than bone, and functions in several processes related to tumor formation 
(Figure-2). Runx2 has been shown to up-regulate several genes related to tumorigenesis, 
including TGFR, VEGF, MMP, Integrins, and IHH (Pratap et al., 2008, Sterling et al., 
2011). 
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Figure-2: Various Stages of Tumor Progression and Runx2 
Target Genes.   Shown are the main stages of tumor formation, 
from left to right and the Runx2-related gene product (blue) that 
helps regulate each process. (Adapted from Dasgupta et al., 
2012) 
  
Each advancing state of cancer involves a Runx2 target gene. At the start of tumor 
progression, the receptor gene for TGF-β (TGFR) is present on the cell surface, which 
allows for cell proliferation. Angiogenesis, the formation of blood vessels surrounding 
the tumor, is supported by vascular endothelial growth factor (VEGF).  MMPs are Runx2 
target genes present when cells become invasive. Integrins, bone sialoprotein (BSP), and 
osteopontin (OP) all play a role in extravasation, the movement of cancer cells present 
within the primary tumor, initially preventing their metastasis to other places in the body, 
such as the bone.   
With respect to PC, the final stage of PC is its metastasis of the cancer to the 
bone. At this point, Indian hedgehog (IHH) and parathyroid hormone-related peptide 
(PTHrP) are detected.  These factors are known to be required for bone resorption 
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(osteolysis) and for endochondral ossification, a process of bone formation (Rivron et al., 
2012). 
Runx2 has been analyzed in metastatic PC3 cells, a human prostate cancer cell 
line (Akech et al., 2010). The expression of Runx2 mRNA and protein was found to be 
higher in PC3 cells compared to non-metastatic cells lines. PC3 cells have also been 
injected into SCID mice bones to make a mouse model of metastatic bone disease.  SCID 
mice, which lack an immune system, can accept human cells when injected in the bone, 
and showed increased osteolysis of the bone that correlated with high levels of Runx2.  
Runx2 involvement in prostate cancer is also linked with tumor metastases because 
Runx2 activates the expression of many genes that affect tumor growth (Akech et al., 
2010). Because Runx2 target genes are known to be involved at different stages of tumor 
growth, discussed above, a future goal is to inhibit Runx2 expression/activity to help 
retard tumor progression. 
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PROJECT PURPOSE 
 
 
Previous studies (discussed in the Background) have shown that transcription 
factor Runx2 controls the expression of a variety of genes related to cancer progression, 
including initial tumor growth, vessel formation, tumor invasion, tumor extravasation, 
and metastasis to the bone.  With respect to prostate cancer (PC), in vitro studies have 
shown that Runx2 is highly expressed in metastatic PC lines.  We postulate that Runx2 is 
likely to be expressed in the prostate gland prior to its metastasis to bone, and helps 
activate genes that facilitate metastatic bone disease.  Specifically, this project will 1) 
examine in vivo Runx 2 expression (mRNA and protein) in mouse PC models (LADY 
and TRAMP), 2) identify the cells expressing Runx2 (including, normal stromal and 
epithelial cells, and cancer cells such as PIN and adenocarcinoma, and 3) determine 
whether a knockdown of Runx2 in TRAMP cells reduces their tumor metastatic 
properties. 
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METHODS 
 
Cells and Reagents 
TRAMP-C2 cells were grown in Dulbecco's modified Eagle's medium (DMEM) 
with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L 
glucose supplemented with 0.005 mg/ml bovine insulin and 10 nM dehydro-
isoandrosterone (androgen), 90%; fetal bovine serum, 5%; Nu-Serum IV, 5%.  TRAMP-
C2 cells were grown in 5% carbon dioxide (CO2) at 37°C. 
Neotag1 cells were grown in (DMEM) containing 2.5% heat-inactivated fetal 
bovine serum,  1% antibiotic-antimycotic (Gibco, Grand Island, NY), 50 μg/ml 
gentamicin (Gibco), 4 µg/ml bovine pituitary extract (Hammond Cell Tech, Windsor, 
CA, USA), 1% insulin-transferrin-selenium-X (Gibco), 50 ng/ml cholera toxin (Sigma, 
St. Louis, MO), 10 ng/ml EGF (Sigma) at 37°C in an atmosphere containing 5% CO2. 
The cells were maintained with 10
-8
 M dihydrotestosterone (DHT, androgen). 
 
 
Mice 
All animal handling was done following IACUC (Institutional Animal Care and 
Use Committee) approved protocols.  RNA samples and cells isolated from the LADY 
mouse model were obtained from our collaborator Dr. S. Kasper (University of 
Cincinnati). The TRAMP mice were obtained from Jackson Laboratories, and bred as 
follows to obtain tumors: 
                                                       Female                      Male 
                                                   Tg TRAMP    X     C57BL/6 WT  
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The offspring Tg-TRAMP males developed tumors by 6 weeks.  Tumors were collected 
at 6, 12, 16, and 21 weeks. Beyond this stage, tumors are very advanced and prolonged 
metastasizing to lung that causes death by 26-33 weeks. 
TRAMP mice were killed using a humane double kill method of overdose of 
isofluorine followed by cervical dislocation.  Mouse prostate, lung, and lymph node 
tissues were obtained from mice by Dr. Jacqueline Akech with assistance from Catherine 
King. The entire organ was excised and allocated to use for RNA isolation, protein 
isolation, or histology. Organs used for RNA were placed in Trizol (Invitrogen, Carlsbad, 
CA), homogenized, and frozen for later use. Organs used for protein were placed in RIPA 
buffer, homogenized, and stored for later use. Organs used for histology were placed in 
fixative in preparation for tissue processing and embedding in paraffin blocks.  
 
Mouse Genotyping for Tumor Positive Mice After Breeding 
Tail genomic DNA was isolated using a Lambda Biotech genomic DNA isolation 
kit (Lambda Biotech, St. Louis, MO). The samples were digested with solution A and 
proteinase-K. Following digestion, the samples were mixed with solution B, and were 
incubated on ice for 10 min, then centrifuged for 10 min at 10,000 rpm. The supernatant 
was transferred to new tubes, and the DNA was precipitated with 100% ethanol, then the 
tubes were centrifuged for 5 min at full speed in a microcentrifuge. The supernatant was 
then discarded, and the DNA pellet was washed with 70% ethanol, air dried, and then re-
suspended in TE buffer. Gene specific primers specific for the transgene were obtained 
from Jackson Laboratories (Bar Harbor, Maine) (see Table I below). 
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Table-I:  Primers Used for Mouse Genotyping. 
Primer Sequence 5’-3’ Primer Type 
oIMR7084 
GCG CTG CTG ACT 
TTC TAA ACA TAA G 
Transgene 
oIMR7085 
GAG TCT ACG TTA 
AGT TTT GAT GTG T 
Transgene 
oIMR7338 
CTA GGC CAC AGA 
ATT GAA AGA TCT 
Internal Positive Control 
oIMR7339 
GTA GGT GGA ATT 
TCT AGC ATC ATC C 
Internal Positive Control 
 
The PCR cycle was 94C for 3 min, 94C for 30 sec, 62C for 1 min, 72C for 1 
min, repeat steps 2-4 for 35 cycles, then 72C for 2 min, and 10C hold.  The PCR 
product was run on a 1.5% agarose gel (Figure 3). When the transgene is present, an 
upper band of 650 kb is present. The lower band represents the positive internal control 
(324 kb), and is present in all DNA samples (TRAMP + and TRAMP -). 
 
Immunohistochemistry 
Prostate tissues acquired from TRAMP mice, and their age matched littermates at 
6, 12, 16, 21 weeks, were obtained using previously described methods (see Animals 
section). In other cases, 33 week old prostate tissues were obtained from our collaborator 
Lucia Languino (University of Massachusetts) to represent late stage prostate cancer.  
Hematoxylin and Eosin staining of tissues was performed initially followed by 
immunohistochemistry to detect Runx2 protein in prostate tumors, essentially in 
accordance with Akech et al (2010) with a few exceptions. Mouse prostate, lung, and 
lymph node tissues were provided in paraffin sections by the histology core of the Stein-
Lian lab. The slides were dipped into xylene solution twice, 10 minutes each for 
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deparaffination.  To rehydrate the tissue, the slides were placed in 99% ethanol three 
times, 10 minutes each, then in 96% ethanol twice for 10 minutes each.  The slides were 
then placed in endogenous peroxidase blocking solution  (1% BSA, 0.2% gelatin, 0.05% 
saponin in PBS) for 30 min, then rinsed in 96% ethanol before being placed in 70% 
ethanol for 10 min. The slides were then briefly rinsed with distilled water, and then 
briefly dipped in 1X Dako Cytomation Target Retrieval solution (pH 6.0) followed by 
antigen retrieval using pressure cooker method for approximately 20 min.  Tissue 
samples were allowed to cool down, and primary antibody Runx2 (mouse monoclonal) at 
a dilution of 1:100 was added and placed at 4C overnight. The slides were then washed 
(0.1% BSA, 0.2% gelatin, 0.05% saponin in PBS) 3 times, 10 min each. Then secondary 
antibody (goat-anti-mouse) was added at a 1:500 dilution for 1 hour. The slides were 
washed again and then received DAB with detection for 10 min. The slides were then 
rinsed in PBS, then in distilled water.  The slides received Hemotoxylin for 2 min, and 
then were rinsed with running water for 20 min. Dehydration of the tissue was done by 
placing the slides in ethanol (70%, 96%, 99%) in order of increasing percentage for 10 
min each. Then they were dipped twice in Xylene for 10 min.  Finally the slides were 
mounted. 
 
Immunoblotting for Runx2 (Western Blot) 
Protein samples, both cellular and tissue, were harvested in RIPA buffer and 
2xSDS sample buffer supplemented with protease inhibitors (Complete, EDTA-free, 
Roche Diagnostics, Mannheim, Germany) and MG132 (Calbiochem, City, State).  For 
protein determination, the Biorad DC protein assay reagent was used (Biorad, Hercules, 
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CA). 50 μg of prostate proteins were separated on a 10% acrylamide gel using SDS-
PAGE. Then the protein was transferred to a PDVF membrane by using 10 volts of 
electricity for 30 min via semi-dry transfer. The membrane was then blocked in 5% milk 
for 1 hour, shaking at room temperature. The membrane was incubated in Runx2 
antibody (made by the Stein-Lian lab) at 1:1000 dilution, shaking at 4C overnight. The 
next day, the membrane was washed 3 times with PBS-T buffer, for 10 min each wash. 
Tubulin mouse monoclonal antibodies (Sigma, St. Louis, MO) at 1:10,000 dilution was 
used as the internal control to ensure equal protein loading. The membrane was incubated 
in secondary peroxidase labeled goat-anti-mouse antibodies (Santa Cruz Biotechnologies, 
Santa Cruz, CA), at a dilution of 1:5000 for 1 hour with shaking at room temperature. 
The membrane was washed 3 times in PBS-T. The signal was detected by chemi-
luminescence (ECL) (Perkin Elmer, Waltham, MA) on Kodak film (Kodak, Rochester, 
NY).  
 
RT-PCR 
Total RNA was isolated using Trizol (Invitrogen) and subjected to DNase I 
digestion to eliminate residual DNA using Zymo DNA-free RNA kit (Zymoresearch, 
Irvine, CA). cDNA preparation was performed using the Superscript II First Strand 
synthesis cDNA  kit  (Invitrogen).  PCR was performed as described above. Gene 
expression was monitored using real-time primer pairs (Table 2) with SYBR Green 
detection (Applied Biosystems, City, State) and analyzed using the ΔΔCT  method.  
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Table 2- RT-PCR Primer Sequences 
Primer Sequence 5’-3’ 
NKX3.1 F ATGCTTAGGGTAGCGGAGC 
NKX3.1 R TGCGGATTGCCTGAGTGTC 
AR F CTGGGAAGGGTCTACCCAC 
AR R GGTGCTATGTTAGCGGCCTC 
Runx2 F CGG CCC TCC CTG AAC TCT 
Runx2 R TGC CTG CCT GGG ATC TGT A 
Runx1 F AGATTCAACCTCAGGTTTGTC 
Runx1 R CGGATTTGTAAAGACGGTGATG 
GAPDH F AGGTCGGTGTGAACGGATTTG 
GAPDH R TGTAGACCATGTAGTTGAGGTCA 
OC F CTGACAAAGCCTTCATGTCCAA 
OC R GCGCCGGAGTCTGTTCACTA 
OP F TTTGCTTTTGCCTGTTTGC 
OP R CAGTCACTTTCACCGGGAGG 
 
Runx2 Knockdown:  Generation of Stable TRAMP cells Expressing Runx2 shRNA 
TRAMP-C2 cells were plated 1x10
6
 per 6-well plate, then grown at 37°C in 5% 
CO2.  At 40% confluence, the cells were infected with 100 μl of lenti-virus expressing 
short hairpins indicated as control empty vector (EV-shRNA) or specific for Runx2 
knockdown (Runx2-shRNA) in complete medium (see materials and methods) containing 
8 μg/ml polybrene. 
UT Ev-sh Runx2-sh 
UT EV-sh Runx2-sh 
 
The plates were spun for 90 min at 37°C at 2400 RPM, then incubated at 37°C in 5% 
CO2. After 24 hours of incubation, the media was changed, then the cells were used for a 
scratch assay, and harvested for RNA and protein isolations.  The effectiveness of the 
Runx2 knockdown was monitored by western blot (see above)  
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Scratch (Wound Healing Assay) 
In vitro wound healing assays were performed with TRAMP-C2 cells expressing 
RUNX2-shRNA or EV-shRNA. Cells were grown until 80% confluence and scratched 
with a 200 μl pipette tip to create a cell free area ('wound’), this was considered the 0 hr 
time point. Cells were washed to remove unattached cells, and incubated for 24 hr and 
examined by light microscopy.  
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RESULTS 
 
 
 
 Because previous studies showed that transcription factor Runx2 controls the 
expression of a variety of genes related to cancer progression, and that Runx2 is highly 
expressed in vitro in metastatic PC lines, we investigated whether Runx2 is expressed in 
the prostate gland just prior to its metastasis to bone.  We began by determining the 
genotype of each mouse. Then tissue, protein, and RNA were analyzed at several time 
points across prostate cancer progression to determine where Runx2 expression was 
increased compared to wild type controls. 
  
Mouse Genotyping and Histology 
C57BL/6 Tg-TRAMP males were created by breeding Tg females to WT males, 
then the DNA of the offspring was analyzed for the presence of the transgene by PCR 
(Figure-3).  Seven positive transgenic mice and 6 negatives were identified (denoted by 
+ or – respectively in the figure). Mice expressing the probasin transgene (PB) in 
TRAMP positive showed expression at 650 bp (Figure 3), while the internal control 
(Casein) was expressed at a slightly lower molecular weight at 324 bp. Previously 
analyzed samples that showed + and – PB expression (lanes 15 and 16 respectively) were 
used as controls for accurate genotyping.  In addition, distilled H2O used in each reaction 
mix was used as readout for the possibility of reagent contamination during sample 
preparation and PCR amplification (lane 17).  Primers for both the transgene and the 
internal control were used simultaneously in the PCR reaction using standardized 
conditions.  Results indicate that correct primers were used to establish PB expression, 
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establishing TRAMP+ mice in the population (Figure 3). However, in some cases 
positive expression of PB transgene was also observed in transgenic female mice (Figure 
3, lane 8).  These mice were not used in subsequent expression experiments for Runx2 or 
target gene expression analysis, but were used for further breeding and generation of 
transgenic TRAMP+ve  male mice as indicated in the methods section.  Our results show 
that the genotype of TRAMP mice could be used successfully to distinguish between 
TRAMP + and TRAMP – mice. All TRAMP - mice within each genotyping experiment 
were aged alongside the TRAMP +ve males for the 6, 12, 16, and 21 week time points.  
 
 
Figure-3: TRAMP PCR Mouse Genotyping. Figure shows amplified DNA 
of the probasin transgene (650 bp, top band) and the internal control (324 
bp, lower band).  Tramp+ and TRAMP- male genotype, and gender (in 
blue) are indicated.  TRAMP+ female genotype is indicated as an asterix.  
Controls used (lane 15, 16, and 17) are TRAMP + male, TRAMP - male 
and H20 respectively. Molecular weight marker used to determine the size 
of migrated DNA is indicated (lane 1). 
 
Once the TRAMP genotype was verified, the prostate tissue was examined at 6, 
12, 16, 21, and 33 weeks by hematoxylin and eosin staining for the presence of PC 
lesions to verify the genotyping results (Figure-4). The histology confirmed that mice at 
6 weeks showed early stages of PC (prostatic intraepithelial neoplasia, PIN), hyperplasia 
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at 16 weeks, neoplasia at 21 weeks, and distal metastases at 33 weeks, while control mice 
lacked all of the above. 
 
 
 
Figure-4: Hematoxylin and Eosin Histology Staining of Prostate Tissue in 
TRAMP Mice at Various Ages.  The H&E staining showed PIN type lesions at 
6 weeks, hyperplasia at 16 weeks, neoplasia at 21 weeks, and distal metastases at 
33 weeks. 
 
 
Analysis of Runx2 Protein and mRNA in Prostate Tissue 
Previous reports showed that Runx2 is highly expressed in aggressive advanced 
stage tissues in human prostate cancer tissue, as well as in PC3 human prostate cancer 
cells (Akech et al., 2010).  Therefore, the presence of Runx2 in tissues from advanced 
late stage prostate cancer was determined by immunohistochemistry (IHC) in 33 week 
old TRAMP mouse prostate tissue compared to age-matched WT tissue (Figure 5).   
Results revealed that Runx2 was expressed in advanced adenocarcinoma, suggesting a 
role of Runx2 in the aggressiveness of tumors in the TRAMP transgenic mouse model.  
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Figure-5:  IHC Analysis of Runx2 Protein Levels in TRAMP 
versus WT Mice.  Upper row denotes IHC for Runx2 protein.  
Lower row denotes H&E staining.  The TRAMP mouse was 
analyzed at 33 weeks, an advanced stage of PC.  
 
  In order to verify whether Runx2 expression is increased with tumor progression, 
western blotting was performed on prostate tissue of TRAMP transgenic mice compared 
to their age-matched WT littermates.  The expression profile (Figure-6) showed that by 
western blot, Runx2 expression did not change in the earlier stages of prostate cancer, 
however a gradual increase was observed at 16 wks and a probable decline to basal levels 
(compared to wild type mice) at 21 wks.  These data suggests that Runx2 expression is 
specifically increased at the onset of adenocarcinoma, and that the expression pattern 
may be dynamic depending on the stage of prostate cancer progression. 
 
 
 
 
 22 
 
Figure-6: Western Blot Analysis of Runx2 Protein Levels in TRAMP versus 
WT Mice.  Western blots for Runx2 or tubulin were performed for WT or 
TRAMP mice at various ages.   The left panel represents a longer exposure of the 
right panel. 
 
A comparison of Runx2 expression in tumor progression was also performed in 
prostate tissues from the LADY mouse model as previously described (Kasper et al., 
1998).   In the LADY mouse, adenocarcinoma is observed at 10 wk time point, and 
advanced tumors are seen between 11 and 15 weeks.   RNA samples obtained from 
prostate tissues of LADY transgenic mice at 2-15 wks compared to their age matched 
littermates were analyzed by standard RT-PCR   The results indicated that Runx2 mRNA 
was expressed throughout disease progression compared to wild type controls (Figure 7).   
Expression was increased with disease progression, but peaked at 15 wks.   
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Figure 7: Expression of Runx2 mRNA in Various Stages of 
Tumor Progression in the LADY Mouse.  RT-PCR showing 
Runx2 expression in mice with prostate cancer, normal prostate 
tissues (left side) do not show Runx2 mRNA expression.    
 
In order to verify Runx2 relative expression in the two transgenic mouse models, 
real time qRT-PCR was performed in tissues from adenocarcinomas of wild type controls 
in the LADY (15 wks) and TRAMP (21 wks).  The results indicated that Runx2 mRNA 
expression is increased several-fold compared to controls in advanced prostate cancer 
(Figure 8).  
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Figure 8: Expression of Runx2 mRNA in Various Stages of Tumor 
Progression in the LADY and TRAMP Mouse Models.  Runx2 expression 
was analyzed by real time qRT-PCR, and is increased compared to control wild 
type mice across prostate cancer progression.  The histobars represent the 
average of 3 determinations, and the error bars denote one standard deviation. 
 
In the TRAMP transgenic mouse model, tumor progression and the role of Runx2 
in the regulation of target gene was examined. RNA isolated from the prostate tissues of 
TRAMP mice and their age-matched littermates were used to determine the relative 
mRNA values across prostate cancer progression (Figure 9).  GAPDH was used as the 
internal control for each sample.  The results show that Runx2 mRNA is increased when 
compared with age-matched controls and it increases across prostate cancer progression 
at 6, 16, and 21 wk time points to represent PIN lesions, and early and late stage 
adenocarcinoma, respectively (Figure 9).  At 12 weeks, the control and experimental 
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values were statistically different, and therefore were not analyzed for subsequent mRNA 
values. 
 
 
Figure 9.  Transcriptional Regulation of Runx2 During Prostate Cancer 
Progression in the TRAMP Mouse Model.  Figure shows the results of real 
time qRT-PCR analysis for six target genes (Runx2, VEGF, OP, AR, NKX3.1, 
and Runx1).  VEGF is a protein involved in tumor vascularization.  Osteopontin 
(OP) is a marker of bone metastasis. Note that expression of the androgen 
receptor (AR), which regulates normal prostate function and NKX3.1 a prostate 
tumor suppressor is lost as tumor progresses in the TRAMP mouse prostate 
tumors. Runx1, which regulates hematopoiesis also decreased. 
 
We then wanted to determine whether knock down of Runx2 expression in both 
TRAMP-C2 and Neotag1 cells indicated a role in transcriptional control.  Runx2 
expression was knocked down by shRNA by lentiviral delivery.  First, the efficiency of 
the lentivirus was determined by examining the infected cells for GFP expression present 
in the lentiviral vectors for EV-shRNA and Runx2-shRNA.  The results revealed 
successful infection of lentivirus (Figure 10, top left panel).  Expression of Runx2 and 
the angiogenesis target gene, VEGF were analyzed by real time qRT-PCR.  Suprisingly, 
we observed an increased and not a decreased expression in Runx2 in both cells lines.  
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Expression of VEGF did not show any change or was statistically insignificant, in 
addition protein expression by western blotting in both TRAMP-C2 and Neotag1 cells 
showed no difference (data not shown).  We attribute these observations possibly to a 
lack of specificity of the short hairpins for targeting mouse Runx2.  Interestingly, when 
we performed functional studies to determine the defined role of Runx2 in tumor 
metastasis using TRAMP-C2 as a cellular model, we observed retarded migration in a 
wound healing (scratch) assay (Figure 10, lower left panel) in Runx2-shRNA compared 
to the EV-shRNA group.  We propose that utilization of a mouse specific Runx2-shRNA 
is essential in these studies for better interpretation, as well as more extensive study with 
Runx2 protein.  
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Figure 10.  Functional Role of Runx2 in Prostate Cancer.   Immuno-
fluorescence shows successful incorporation of lentivirus (encoding Runx2 
shRNA) into TRAMP-C2 and NeoTag1 cells (Top left). Wound healing assay 
shows slowed growth of Runx2-shRNA infected cells across scratch after 24 
hours compared to EV-shRNA infected cells (Bottom left).  qRT-PCR 
determined an unexpected increase in Runx2 in Runx2-shRNA infected 
TRAMP-C2 and NeoTag1 cells (Top right). VEGF levels showed no change in 
Runx2-shRNA infected cells (Bottom right). 
 
 
 
 28 
DISCUSSION 
 
The results of this project showed a dynamic expression of Runx2 in the TRAMP 
mouse prostate tissue throughout the progression of prostate cancer. qRT-PCR and 
western blot results showed a distinct increase in Runx2 mRNA and protein expression at 
16 wks in TRAMP + mice compared to age-matched littermates (Figures 9 and 6, 
respectively). Analysis of Runx2 and Runx2 target genes across the progression of 
prostate cancer support the findings that 16 wk is a critical time point, because this is 
when expression of metastatic genes increase in TRAMP + mice compared to age 
matched littermates (Figure 9). Immunohistochemistry confirms increased expression in 
Runx2 in a 33 wk old TRAMP + mouse compared to a 33 wk old wild type mouse 
(Figure 5). Figure 8 shows mRNA expression of Runx2 in advanced prostate cancer in 
both the LADY and TRAMP mouse models.  The results show an increase in Runx2 in 
both models compared to wild type controls. Figure 7 clearly shows the presence of 
Runx2 in the LADY prostate cancer model compared to wild type mice, which showed 
no Runx2 expression. Prostate cancer cell lines were also analyzed, but require further 
testing (Figure 10).  From figure 10, Runx2 knock down was not observed in mRNA, but 
slowed growth can be seen in the wound-healing assay, which is indicative that Runx2 
plays a role in migration and metastasis. Further analysis is needed for conclusive results.  
These results indicate that a potential therapy, which targets Runx2, would aim to 
reduce the Runx2 increase seen at the 16 week time point, and would therefore disturb 
the normal progression of prostate cancer.  
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Future projects might include repeating lentiviral infection of Runx2sh-RNA 
knockdown experiments, Runx2 over-expression experiments, and further analysis of 
Runx2 target genes involved in metastasis and cancer progression. One reason the knock 
down did not work could have been that the sh-RNA was targeting human Runx2 and 
was used in mouse cell lines (TRAMP-C2 and NeoTag1). Another reason could be that 
the sh-RNA is not specific and is not targeting the correct area of gene expression. To 
correct this, an inducible system could be used when infecting the cells to ensure 
lentiviral incorporation and sh-RNA success. Another option would be to create a clone 
of Runx2-shRNA which targets mouse Runx2. This would increase the probability of 
Runx2 knock down in mouse cell lines. Once the Runx2-shRNA has been successfully 
knocked down in prostate cancer cell lines, the knock down could be introduced into 
prostate cancer mouse models (TRAMP and LADY). The effects would be characterized 
and used to discovery new therapies for prostate cancer. The over-expression experiments 
would include analysis of mRNA, and protein in cell lines to provide information on the 
function of Runx2.  Runx2 target genes and cancer markers should be analyzed (both 
mRNA and protein) across prostate cancer progression in TRAMP mice to correlate the 
expression of Runx2 and the progression of prostate cancer in vivo. 
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